An overview of the anti-HIV potential of thiazolidinone derivatives

• Main Authors: Mohamed A. Abid, Fatma, Salim, Nurul Syahirah, Abdul Wahab, Roswanira, Hashim, Siti Ernieyanti, Sankaranarayanan, Murugesan, Bhat, Ajmal, Jamalis, Joazaizulfazli
• Format: Article
• Published: Bentham Science Publishers 2023
• Subjects: QD Chemistry
• Online Access: http://eprints.utm.my/105027/; http://dx.doi.org/10.2174/2211352521666230718094413

Human immunodeficiency virus (HIV) is the cause of acquired immunodeficiency syndrome (AIDS), an immunosuppressive, life-threatening condition that frequently results in other potentially fatal opportunistic infections in affected patients. Despite advancements in anti-retro-viral therapy, AIDS remains the main reason for worldwide mortality. Although various anti-HIV drugs have profoundly enhanced the quality of life for AIDS patients, some patients develop resistance to the drugs, and the long-term anti-HIV treatments, and their adverse effects, prevail as major therapeutic failure causes. Therefore, concerted efforts by the scientific community are cru-cial to identifying new candidates for anti-HIV therapies. In this respect, the thiazolidinone moiety has acquired prominence in drug discovery and development due to its antifungal, antiviral, anti-depressant, anticancer, and antibacterial properties. This moiety also demonstrated significant anti-HIV activity as a core heterocycle or derivative of substituted heterocycles. To expedite the synthesis of more novel anti-HIV drugs containing a thiazolidinone nucleus, we compiled a list of thiazolidinone-containing previously documented anti-HIV compounds. We hope that this could serve as a guide for future researchers in their design of effective thiazolidine-containing compounds showing anti-HIV activity.